メタ情報
| meta description平均長 | 246.9 |
|---|
| OGPありページ数 | 20 |
|---|
| Twitterカードありページ数 | 20 |
|---|
内部リンク分析(Internal)
| ユニーク内部リンク数 | 103 |
|---|
| ページあたり内部リンク平均 | 22.7 |
|---|
キーワード分析(KeywordMap)
ワードクラウド上位
| 語 | 重み |
|---|
| capital | 1 |
| profit | 0.968122 |
| licensing | 0.850216 |
| million | 0.838482 |
| out | 0.837894 |
| net | 0.803371 |
| term | 0.722154 |
| supply | 0.629435 |
| Company | 0.612031 |
| dividend | 0.60913 |
| through | 0.602508 |
| can | 0.586303 |
| policy | 0.568437 |
| evaluation | 0.529844 |
| loss | 0.527913 |
| operating | 0.525592 |
| level | 0.517761 |
| high | 0.511881 |
| structure | 0.508989 |
| value | 0.49568 |
| price | 0.470041 |
| services | 0.465085 |
| contract | 0.456848 |
| ROIC | 0.456472 |
| IDD | 0.455913 |
| while | 0.452532 |
| medium | 0.449438 |
| investments | 0.448875 |
| was | 0.445114 |
| margin | 0.44382 |
| phase | 0.436544 |
| Business | 0.430634 |
| plan | 0.430634 |
| stable | 0.425231 |
| CNS | 0.416812 |
| FY2025 | 0.415439 |
| also | 0.405902 |
| SHED | 0.400781 |
| gross | 0.396183 |
| turnover | 0.394303 |
| based | 0.385765 |
| negative | 0.38475 |
| financial | 0.378958 |
| current | 0.370345 |
| ROE | 0.363214 |
| forward | 0.357337 |
| improvement | 0.356091 |
| there | 0.355326 |
| upfront | 0.352687 |
| process | 0.352687 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| licensing | out | 4.918533 | 260 |
| billion | yen | 4.687395 | 804 |
| items | short | 4.68162 | 320 |
| cells | iPS | 4.681467 | 240 |
| COVID | looks | 4.626451 | 160 |
| anti | humanised | 4.492912 | 240 |
| medium | term | 4.450379 | 365 |
| information | website | 4.382897 | 240 |
| late | stage | 4.36653 | 168 |
| biosimilar | third | 4.335668 | 180 |
| milestone | payments | 4.32423 | 164 |
| COVID | OBP | 4.298683 | 160 |
| clinical | trials | 4.159713 | 617 |
| agreement | licence | 4.150485 | 160 |
| Biotech | Inc | 4.126432 | 108 |
| CD3 | multispecificity | 4.079283 | 80 |
| Henlius | Shanghai | 4.079283 | 80 |
| Hong | Kong | 4.079283 | 80 |
| Kong | Macau | 4.079283 | 80 |
| compliant | regulations | 4.079283 | 80 |
| estimates | stemchymal | 4.079283 | 80 |
| spinocerebellar | stemchymal | 4.079283 | 80 |
| degeneration | spinocerebellar | 4.079283 | 80 |
| Cancer | leukemia | 4.079283 | 80 |
| Hence | faster | 4.079283 | 80 |
| medicines | molecule | 4.079283 | 80 |
| Delivers | reasonably | 4.079283 | 80 |
| Acquisition | radiopharmaceutical | 4.079283 | 80 |
| Following | commercialisation | 4.079283 | 80 |
| Exfoliated | Human | 4.079283 | 80 |
| Deciduous | Exfoliated | 4.079283 | 80 |
| Interesting | exploration | 4.079283 | 80 |
| Focus | nucleic | 4.079283 | 80 |
| acid | nucleic | 4.079283 | 80 |
| AccuRna | CY2020 | 4.079283 | 80 |
| Remains | acquisitive | 4.079283 | 80 |
| Heptares | purchase | 4.079283 | 80 |
| Stemchymal | experimentation | 4.079283 | 80 |
| Acquiring | radiphamaceutical | 4.079283 | 80 |
| Film | Fuji | 4.079283 | 80 |
| Bank | Royalty | 4.079283 | 80 |
| border | peeling | 4.079283 | 80 |
| 5LBT | Canada | 4.079283 | 80 |
| 5LBT | herpetic | 4.079283 | 80 |
| herpetic | neuralgia | 4.079283 | 80 |
| Completion | Review | 4.079283 | 80 |
| Report | Review | 4.079283 | 80 |
| CRL | Report | 4.079283 | 80 |
| hydrochloride | ripasudil | 4.079283 | 80 |
| hydrate | hydrochloride | 4.079283 | 80 |
被リンク情報
このデータの閲覧には会員登録が必要になります。会員登録